Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported financial results for the third quarter ended September 30, 2018, along with a general business update. Aerie Highlights Rhopressa® (netarsudil ophthalmic solution) 0.02% generated t